Biodel Reports First Quarter Fiscal Year 2016 Financial

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Biodel Reports First Quarter Fiscal Year 2016 Financial Results

DANBURY, CT --(Marketwired - February 16, 2016) - Biodel Inc. ( NASDAQ : BIOD ) today reported financial results for the first fiscal quarter ended December 31, 2015.

Corporate updates since last fiscal quarter:

  • In October 2015, the company committed to a restructuring plan designed to reduce infrastructure costs and improve efficiency of research and quality-related activities. The company estimated that it will incur one-time cash severance payments of approximately $0.3 million in connection with the October 2015 restructuring and reduce its cash burn by approximately $2 million annually.
  • In December 2015, the company announced a plan to explore strategic alternatives to further realize value from its pipeline assets and to preserve the company's cash balance. 
  • In January 2016, the company committed to an additional restructuring plan designed to further reduce operating costs while it evaluates its strategic alternatives. The company estimated that it will incur one-time cash severance payments of approximately $1.3 million in connection with the January 2016 restructuring and will reduce its average operating cash burn to approximately $1.1 million per quarter.
  • The company has retained Ladenburg Thalmann & Co. to assist with the review of strategic alternatives. Also, the company announced in January 2016 that its board of directors appointed Gary G. Gemignani as interim chief executive officer, with primary responsibility of managing the strategic alternatives process.

"As recently announced, we have significantly reduced our operating cash burn and are focused on exploring strategic alternatives that can provide substantial value to our shareholders," said Gary Gemignani, Biodel's interim CEO. "While we cannot predict the timing of when the process may conclude, we plan to execute expeditiously and look forward to providing an update as we move forward."

First Quarter Financial Results

Biodel reported a net loss of $3.2 million, or $0.05 per share for the quarter ended December 31, 2015. These results compare to a net loss of $4.7 million, or $0.20 per share, for the quarter ended December 31, 2014.

Biodel did not recognize any revenue during the quarter ended December 31, 2015 or 2014. 

At December 31, 2015, Biodel had cash and cash equivalents of $37.0 million and 64.1 million shares of common stock outstanding.

 
Biodel Inc.
Condensed Consolidated Balance Sheets
(in thousands, except share and per share amounts)
                 
      September 30, 2015       December 31, 2015  
              (unaudited)  
ASSETS                
 Current:                
  Cash and cash equivalents   $ 40,845     $ 36,932  
  Restricted cash     -       21  
  Prepaid and other assets     262       674  
                   
    Total current assets     41,107       37,627  
  Property and equipment, net     280       251  
  Intellectual property, net     37       36  
                   
    Total assets   $ 41,424     $ 37,914  
                 
LIABILITIES AND STOCKHOLDERS' EQUITY                
Current:                
  Accounts payable   $ 421     $ 335  
  Accrued expenses:                
    Clinical trial expenses     1       136  
    Payroll and related     863       282  
    Accounting and legal fees     289       324  
    Other     234       335  
  Income taxes payable     -       8  
                   
      Total current liabilities     1,808       1,420  
                   
  Common stock warrant liability     5       3  
  Other long term liabilities     54       38  
                   
      Total liabilities     1,867       1,461  
Commitments                
  Stockholders' equity:                
  Convertible preferred stock, $.01 par value; 50,000,000 shares authorized; 1,909,410 and 0 issued and outstanding     19       -  
  Common stock, $.01 par value; 200,000,000 shares authorized; 62,151,202 and 64,148,271 issued and outstanding     622       641  
  Additional paid-in capital     287,212       287,323  
  Accumulated deficit     (248,296 )     (251,511 )
                   
    Total stockholders' equity     39,557       36,453  
                   
    Total liabilities and stockholders' equity   $ 41,424     $ 37,914  
                 
                 
 
Biodel Inc.
Condensed Consolidated Statements of Operations
(in thousands, except share and per share amounts)
(unaudited)
             
    Three Months Ended December 31,  
    2014     2015  
Revenue $ -   $ -  
             
Operating expenses:            
  Research and development   3,407     1,594  
  General and administrative   1,833     1,632  
             
Total operating expenses   5,240     3,226  
Other (income):            
  Interest and other income   (9 )   (17 )
  Adjustment to fair value of common stock warrant liability   (546 )   (2 )
             
Loss before tax provision   (4,685 )   (3,207 )
Tax provision   2     8  
             
Net loss   (4,687 )   (3,215 )
             
             
Net loss per share - basic and diluted $ (0.20 ) $ (0.05 )
             
Weighted average shares outstanding - basic and diluted   23,435,844     63,583,137  
             
             

About Biodel Inc.

Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes that may be safer, more effective and more convenient for patients. Biodel's product candidates are developed by applying proprietary technologies to existing drugs in order to improve their therapeutic profiles. More information about Biodel is available at  www.biodel.com .

Safe-Harbor Statement

This press release contains forward-looking statements. All statements that address operating performance, or other events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements are based on management's beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in "Item 1A. Risk Factors" and elsewhere in our most recent Annual Report on Form 10-K and those described from time to time in other reports which we file with the Securities and Exchange Commission. 

BIOD-G

CONTACT: Clayton Robertson The Trout Group +1 (646) 378 2964

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Aimbient's OR Timestamp Study Puts Efficiency to Test

Updated Category News Views 160

A camera catching a patient’s arrival on time may sound mundane, but operating rooms are where mundane details can turn into serious money and better operational decisions. Aimbient’s newly corrected announcement points to an independently conducted Stanford Medicine study in JAMA Surgery that tested whether its computer-vision system could document key operating-room...

Continue Reading
Linq's $90M Bet on the Infrastructure Behind AI Agents

Updated Category News Views 193

Ninety million dollars just landed on the least glamorous part of the AI-agent rush: the pipes. Linq, the San Francisco private company, announced the round on November 18, 2026, led by Andreessen Horowitz, with returning backing from TQ Ventures, Mucker Capital and Abstract, plus new money from Anthos and Left Lane Capital. Ben Horowitz is joining the board. That is a...

Continue Reading
Mudrick Urges Doncasters to Test a Strategic Sale Now

Updated Category News Views 0

Castings are rarely glamorous until nobody can get them, and Mudrick Capital is betting that ugly little industrial reality could make Doncasters worth far more in a takeover than the market currently credits. The event-driven investor, which says it owns roughly 4.3% of DPC Holdings Limited, has asked the board to quietly evaluate strategic alternatives, including a sale...

Continue Reading
1095 Days Finds the Army's Long, Ordinary War Life

Updated Category News Views 125

A cracked barracks window can explain more than a polished battlefield legend. Dean R. Cherry's 1095 Days: Three Years in the Green Machine, newly released by Palmetto Publishing, puts its weight on the parts of Army life that war stories often shove into the background: cold, waiting, paperwork, arbitrary rules, lousy living conditions, and the private mental math of...

Continue Reading
Insta360 Tests Holiday Demand With $170 Gear Discounts

Updated Category News Views 102

A discount banner can reveal plenty about a hardware brand's priorities, and Insta360's latest Black Friday push is plainly built to put more of its ecosystem into customers' hands. The company is advertising savings of up to US$170 across cameras, gimbals, microphones, webcams, and accessories, with the promotion available for a limited time through its own store and...

Continue Reading
Health In Tech Gets a Real Distribution Test in 2027

Updated Category News Views 67

A 100,000-employee funnel is the sort of number that makes a small InsurTech investor sit up, then reach for the fine print. Health In Tech has brought a national third-party administrator onto its eDIYBS platform, giving the company access to a TPA serving more than 650 employers in over 40 states, with more than 100,000 covered employees as of May 2026. That is...

Continue Reading
Institutions Spread AI Bets as 2027 Risks Mount Higher

Updated Category News Views 48

Money managers are not fleeing the party; they are checking the fire exits. Natixis Investment Managers surveyed 515 institutions overseeing $42.7 trillion, and their 2027 posture is pretty plain: keep taking risk, just stop pretending every risk is the same. Inflation, rates, government debt, geopolitical fracture and an AI spending boom are all tugging at portfolios at...

Continue Reading
FAMID's Six-Month IVDR Win Opens Europe's Market Door

Updated Category News Views 55

A six-month regulatory sprint is the sort of result that makes a crowded diagnostics field pause and squint. DNV has issued an IVDR certificate to FAMID Biomedical Technology for its E7 Oncoprotein Rapid Test Kit, a Class C in vitro diagnostic intended to aid diagnosis of cervical epithelial cell lesions through detection of HPV E7 oncoprotein in cervical cell samples....

Continue Reading
Teachers in Space Takes Its Classroom Model Orbital

Updated Category News Views 131

Two teachers strapped into a research flight may sound like a glossy space-age photo op, but the useful part of this plan sits back in the classroom with the students staring at the data. Teachers in Space wants to send two educators aboard a Virgin Galactic research flight expected in 2027, and it is raising $2 million to fund the broader educational program and mission....

Continue Reading
Roof Leaks Demand Diagnosis Before the Repair Bill

Updated Category News Views 95

A brown ring on a ceiling is often the last witness, not the crime scene. That is the useful, unglamorous point in Jonathan Floyd's HelloNation discussion of roof leaks: water has plenty of ways to move after it slips past a roof's defenses. Homeowners understandably stare at the stain and assume the answer sits directly overhead. Sometimes it does. Plenty of times, it...

Continue Reading

Top 5 Most Recently Viewed Articles

BioMarin's Strong 2024 Performance Fuels 2025 Expectations

Updated Category News Views 392

BioMarin's Empowering Growth Journey Into 2025 BioMarin Pharmaceutical Inc. has marked a significant achievement with its record performance in 2024, setting a strong foundation for the upcoming year. The company demonstrated robust operational execution and is gearing up for a year of potential double-digit revenue growth as it advances its corporate strategy focusing on...

Continue Reading
Berkshire Hills Bancorp Declares Cash Dividend for Shareholders

Updated Category News Views 104

Berkshire Hills Bancorp Announces Quarterly Dividend Berkshire Hills Bancorp, Inc. (NYSE: BHLB) has recently declared a quarterly cash dividend of $0.18 per common share for its shareholders. This decision by the Board of Directors aims to reward shareholders who are on record by a specified date. Details of the Dividend Announcement The approved cash dividend will be...

Continue Reading
Maiden United Transforms Adele's Skyfall into Heavy Metal Epic

Updated Category News Views 167

Maiden United Transforms Iconic Adele Song into Heavy Metal What if Iron Maiden had recorded the legendary James Bond theme song? Maiden United, a notable tribute band dedicated to Iron Maiden, has taken that intriguing concept and turned it into reality. The band has just unveiled their latest EP entitled Agent 666, which features an electrifying heavy metal cover of...

Continue Reading
Cherokee Federal Boosts Growth with MSI, LLC Investment

Updated Category News Views 213

Cherokee Federal Expands Presence Through Strategic Investment Cherokee Federal, a division of Cherokee Nation Businesses (CNB), has recently announced a significant move in the federal contracting realm. They have acquired a majority stake in Management Science and Innovation, LLC, also known as MSI. This strategic investment marks another milestone under their...

Continue Reading
Metallurgical Coal Market Expected Growth Amid Steel Demand Spike

Updated Category News Views 125

Growth of the Metallurgical Coal Market The global metallurgical coal market is poised for significant growth, estimated at USD 95.27 billion from 2024 to 2028. This growth is largely driven by the increasing demand for steel, which is essential for numerous infrastructure projects around the world. As smart city developments surge, the necessity for high-quality steel...

Continue Reading